Study details how exosomes, released by the breast tumor, tricks cells in the blood-brain barrier into taking them up

by Children's Hospital BostonExtracellular vesicles, also known as exosomes, cross the blood-brain barrier via a transcytosis process. Credit: Kristin Johnson/Vascular Biology Program, Boston

Updated on: May 31,2024

Study details how exosomes, released by the breast tumor, tricks cells in the blood-brain barrier into taking them up

by Children's Hospital BostonExtracellular vesicles, also known as exosomes, cross the blood-brain barrier via a transcytosis process. Credit: Kristin Johnson/Vascular Biology Program, Boston

Updated on:May 31,2024

Adding pembrolizumab to chemo improves survival in cervical cancer, finds study

by Elana GotkineFor women with persistent, recurrent, or metastatic cervical cancer, adding pembrolizumab to chemotherapy, with or without bevacizumab, is associated with improved overall and progress

Updated on: January 23,2024

Adding pembrolizumab to chemo improves survival in cervical cancer, finds study

by Elana GotkineFor women with persistent, recurrent, or metastatic cervical cancer, adding pembrolizumab to chemotherapy, with or without bevacizumab, is associated with improved overall and progress

Updated on:January 23,2024

Study explains how 'zombie' cancer cells revive themselves

by Andrew Smith,Rutgers UniversityGraphical abstract. Credit:Cell Genomics(2023). DOI: 10.1016/j.xgen.2023.100293Mutating cells can prevent the spread of cancer by flipping themselve

Updated on: February 03,2024

Study explains how 'zombie' cancer cells revive themselves

by Andrew Smith,Rutgers UniversityGraphical abstract. Credit:Cell Genomics(2023). DOI: 10.1016/j.xgen.2023.100293Mutating cells can prevent the spread of cancer by flipping themselve

Updated on:February 03,2024

Study finds 5-year relative survival rate of 59.6 percent in lower-risk myelodysplastic syndromes

by Elana Gotkine HealthDay ReporterAbout 40 percent of patients with lower-risk myelodysplastic syndromes (LR-MDS) die of MDS within five years, according to a study published online Nov. 6 in the&nbs

Updated on: January 23,2024

Study finds 5-year relative survival rate of 59.6 percent in lower-risk myelodysplastic syndromes

by Elana Gotkine HealthDay ReporterAbout 40 percent of patients with lower-risk myelodysplastic syndromes (LR-MDS) die of MDS within five years, according to a study published online Nov. 6 in the&nbs

Updated on:January 23,2024

Restoring the gut biome after antibiotics could lead to better outcomes for ovarian cancer patients

by Cleveland ClinicCredit: Pixabay/CC0 Public DomainAntibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression and lower survival r

Updated on: January 30,2024

Restoring the gut biome after antibiotics could lead to better outcomes for ovarian cancer patients

by Cleveland ClinicCredit: Pixabay/CC0 Public DomainAntibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression and lower survival r

Updated on:January 30,2024

Researchers discover iron-targeting approaches to halt proliferation of cancer cells

by University of Arizona(From left) Yu-Shien Sung, doctoral student in the Tomat Lab, and University of Arizona Cancer Center member Elisa Tomat, PhD, are studying an iron-targeting molecule that

Updated on: February 20,2024

Researchers discover iron-targeting approaches to halt proliferation of cancer cells

by University of Arizona(From left) Yu-Shien Sung, doctoral student in the Tomat Lab, and University of Arizona Cancer Center member Elisa Tomat, PhD, are studying an iron-targeting molecule that

Updated on:February 20,2024

Novel immunotherapy agent safe, shows promise against high-risk prostate cancers

byJohns Hopkins University School of MedicinePatient consort diagram and efficacy outcomes in the neoadjuvant treatment of patients with PCa using enoblituzumab. Credit:Nature Medicine&nbs

Updated on: January 15,2024

Novel immunotherapy agent safe, shows promise against high-risk prostate cancers

byJohns Hopkins University School of MedicinePatient consort diagram and efficacy outcomes in the neoadjuvant treatment of patients with PCa using enoblituzumab. Credit:Nature Medicine&nbs

Updated on:January 15,2024

New compounds target and kill brain cancer cells after being energized by low X-ray dose

by Nanyang Technological UniversityResearch fellow Dr Huang Jingsheng from NTU Singapore's School of Chemistry, Chemical Engineering and Biotechnology preparing new anti-brain cancer compound

Updated on: March 05,2024

New compounds target and kill brain cancer cells after being energized by low X-ray dose

by Nanyang Technological UniversityResearch fellow Dr Huang Jingsheng from NTU Singapore's School of Chemistry, Chemical Engineering and Biotechnology preparing new anti-brain cancer compound

Updated on:March 05,2024

Novel T cell receptor therapy shows early anti-tumor activity

byUniversity of Texas M. D. Anderson Cancer CenterCredit: CC0 Public DomainAfamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A

Updated on: January 15,2024

Novel T cell receptor therapy shows early anti-tumor activity

byUniversity of Texas M. D. Anderson Cancer CenterCredit: CC0 Public DomainAfamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A

Updated on:January 15,2024

Mass spectrometry can monitor treatment response in multiple myeloma

by Elana GotkineFor patients with newly diagnosed multiple myeloma (MM), mass spectrometry (MS) can monitor treatment response, according to a study published online Jan. 4 inBlood Cancer Journa

Updated on: February 23,2024

Mass spectrometry can monitor treatment response in multiple myeloma

by Elana GotkineFor patients with newly diagnosed multiple myeloma (MM), mass spectrometry (MS) can monitor treatment response, according to a study published online Jan. 4 inBlood Cancer Journa

Updated on:February 23,2024

New calculation tool identifies a group of cancer patients with favorable prognosis

by Centro de Investigación Médica Aplicada (CIMA) Universidad de NavarraResearchers from Cima and Clinica University of Navarra have developed a calculator that identifies patients with multiple myelo

Updated on: January 12,2024

New calculation tool identifies a group of cancer patients with favorable prognosis

by Centro de Investigación Médica Aplicada (CIMA) Universidad de NavarraResearchers from Cima and Clinica University of Navarra have developed a calculator that identifies patients with multiple myelo

Updated on:January 12,2024

Cancer drug restores immune system's ability to fight tumors

by University of Texas at AustinCredit: Pixabay/CC0 Public DomainA new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The Universit

Updated on: March 06,2024

Cancer drug restores immune system's ability to fight tumors

by University of Texas at AustinCredit: Pixabay/CC0 Public DomainA new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The Universit

Updated on:March 06,2024